Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure–Response Analyses of a Pivotal Phase I/II Study

Mobocertinib is an oral tyrosine kinase inhibitor approved for treatment of patients with locally advanced or metastatic non‐small cell lung cancer (mNSCLC) with epidermal growth factor receptor gene (EGFR) exon 20 insertion (ex20ins) mutations previously treated with platinum‐based chemotherapy. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Largajolli, Anna, Witjes, Han, Diderichsen, Paul M., Zhang, Steven, Hanley, Michael J., Lin, Jianchang, Mehta, Minal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540490/
https://www.ncbi.nlm.nih.gov/pubmed/35467009
http://dx.doi.org/10.1002/cpt.2622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540490/
https://www.ncbi.nlm.nih.gov/pubmed/35467009
http://dx.doi.org/10.1002/cpt.2622

Ejemplares similares